Phibro Animal Health Corporation (NASDAQ:PAHC) Given Average Recommendation of “Hold” by Brokerages

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $38.80.

A number of research analysts recently weighed in on the stock. Citigroup decreased their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a report on Friday, February 6th.

Phibro Animal Health Stock Performance

PAHC stock opened at $30.79 on Monday. The company’s 50-day simple moving average is $48.45 and its 200-day simple moving average is $45.64. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a 52-week low of $22.85 and a 52-week high of $60.08. The firm has a market cap of $1.25 billion, a P/E ratio of 13.21, a PEG ratio of 0.47 and a beta of 0.47.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, equities analysts forecast that Phibro Animal Health will post 3.07 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be issued a $0.12 dividend. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.6%. Phibro Animal Health’s dividend payout ratio is presently 20.60%.

Insider Buying and Selling

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the sale, the chief executive officer owned 56,152 shares in the company, valued at approximately $2,722,810.48. This represents a 7.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 74,928 shares of company stock valued at $4,017,273. 50.13% of the stock is currently owned by corporate insiders.

Institutional Trading of Phibro Animal Health

A number of hedge funds have recently bought and sold shares of PAHC. Vanguard Group Inc. increased its holdings in shares of Phibro Animal Health by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after buying an additional 13,884 shares during the last quarter. State Street Corp increased its holdings in shares of Phibro Animal Health by 5.4% during the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after buying an additional 48,243 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after buying an additional 626,492 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Phibro Animal Health by 5.8% during the 1st quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock worth $31,899,000 after buying an additional 31,435 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after buying an additional 21,951 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.